Chemistry:Rongliflozin
From HandWiki
Rongliflozin is an SGLT2 inhibitor developed as a potential treatment for diabetes.[1][2]
References
- ↑ "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics 42 (5): 892–905.e3. May 2020. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.
- ↑ "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism 22 (2): 191–202. February 2020. doi:10.1111/dom.13887. PMID 31588657.
 |  |
